fool.com /3 weeks ago

Viking (VKTX) Q3 2026 Earnings Call Transcript

VK2735 obesity drug shows up to 22% weight loss with less frequent dosing schedules.

Read source
fool.com /4 days ago

Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.

Even a small share of the massive market for weight loss drugs could lead to a significant increase in this company's share price.

Read source
fool.com /1 month ago

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing

The company continues to make good progress with its key obesity treatment drug, VK2735.

Read source
fool.com /1 month ago

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Read source
seekingalpha.com /4 weeks ago

Corporación Inmobiliaria Vesta, S.A.B. de C.V. (VTMX) Q3 2026 Earnings Call Transcript

Read source
fool.com /1 month ago

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Read source
fool.com /1 month ago

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

The biotech player could eventually rival big pharma companies.

Read source
fool.com /1 month ago

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

The weight loss drug company continues to make progress, but its share price is bouncing around with events.

Read source
fool.com /4 weeks ago

Vesta (VTMX) Q3 2026 Earnings Call Transcript

Record leasing activity and debt paydown fuel guidance hikes for Mexican industrial REIT.

Read source
fool.com /1 month ago

Prediction: This Stock Could Double Over the Next 5 Years

The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock.

Read source
fool.com /1 week ago

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.

Read source
fool.com /1 month ago

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Read source
fool.com /2 weeks ago

Vertex (VRTX) Q3 2026 Earnings Call Transcript

Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly.

Read source
fool.com /2 weeks ago

Travere (TVTX) Q3 2026 Earnings Call Transcript

FILSPARI sales hit $200.2 million as FSGS launches alongside sustained IgAN demand.

Read source
seekingalpha.com /3 weeks ago

VNV Global AB (publ) (VSTKF) Q3 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 week ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript

Read source
biopharmadive.com /2 weeks ago

Vertex, ahead of FDA decision, calms fears surrounding kidney drug

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future. 

Read source
seekingalpha.com /2 weeks ago

Vext Science, Inc. (VEXTF) Q3 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 week ago

Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow

Read source
seekingalpha.com /1 month ago

Critica Limited (VTMLF) Discusses Mt Lindsay Scoping Study Results and Development Pathway for Tin-Tungsten Project Tran...

Read source
seekingalpha.com /1 month ago

Vertu Motors plc (VTMTF) Q2 2027 Earnings Call Transcript

Read source
seekingalpha.com /1 month ago

Major earnings expected before the bell on Tuesday include:

Read source
seekingalpha.com /4 weeks ago

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Read source
seekingalpha.com /2 weeks ago

Virtus KAR Small-Mid Cap Growth Fund Q3 2026 Commentary

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.